Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment — XAIENT  

Atrial Fibrillation Clinical Trial

Official title: A Prospective, Non-interventional, Multicenter Observational Study to Evaluate the Effectiveness and Safety of Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment

Status Recruiting

Clinical Trial Summary

Study Type and Design Prospective, Observational Study Rivaroxaban in Elderly AF patients with or without renal impairment in Korea

This study will investigate effectiveness and safety in elderly patients, the result from well-designed and high-quality prospective clinical registry collected through real-world clinical practice is expected to resolve current medical unmet needs of rivaroxaban in Korean elderly patients.

Primary Study Objective(s) To investigate the effectiveness of rivaroxaban in elderly patients with NVAF, with or without renal impairment in Korea real-world clinical practice settings Secondary Study Objective(s) To see safety outcome including major bleeding, clinically non-major bleeding, all-cause mortality rivaroxaban in subgroup based on risk factor(eg. Renal impairment) physicians' treatment pattern in rivaroxaban

Clinical Trial Description

Study Population Elderly patients with age ≥ 65 years with treatment naïve or treatment-experienced patients who are diagnosed with NVAF Expected number of patient enrollment is about 1200 patients, Samsung Medical Center is aim to enroll about 200 patients ;

Related Conditions & MeSH terms

• Atrial Fibrillation
• Elderly
• Renal Insufficiency
• Rivaroxaban

• NCT number: NCT04096547
• Study type: Observational
• Source: Samsung Medical Center
• Status: Recruiting
• Start date: September 25, 2019
• Completion date: August 30, 2022